| Antibodies to interleukin-2 elicit selective T cell subset potentiation through distinct conformational mechanisms JB Spangler, J Tomala, VC Luca, KM Jude, S Dong, AM Ring, P Votavova, ... Immunity 42 (5), 815-825, 2015 | 232 | 2015 |
| In vivo expansion of activated naive CD8+ T cells and NK cells driven by complexes of IL-2 and anti-IL-2 monoclonal antibody as novel approach of cancer immunotherapy J Tomala, H Chmelova, T Mrkvan, B Rihova, M Kovar The Journal of Immunology 183 (8), 4904-4912, 2009 | 120 | 2009 |
| Engineering a single-agent cytokine/antibody fusion that selectively expands regulatory T cells for autoimmune disease therapy JB Spangler, E Trotta, J Tomala, A Peck, TA Young, CS Savvides, ... The Journal of Immunology 201 (7), 2094-2106, 2018 | 64 | 2018 |
| Severe, but not mild heat-shock treatment induces immunogenic cell death in cancer cells I Adkins, L Sadilkova, N Hradilova, J Tomala, M Kovar, R Spisek Oncoimmunology 6 (5), e1311433, 2017 | 57 | 2017 |
| Overcoming multidrug resistance via simultaneous delivery of cytostatic drug and P-glycoprotein inhibitor to cancer cells by HPMA copolymer conjugate L Sivak, V Subr, J Tomala, B Rihova, J Strohalm, T Etrych, M Kovar Biomaterials 115, 65-80, 2017 | 53 | 2017 |
| The structure-dependent toxicity, pharmacokinetics and anti-tumour activity of HPMA copolymer conjugates in the treatment of solid tumours and leukaemia B Tomalova, M Sirova, P Rossmann, R Pola, J Strohalm, P Chytil, V Cerny, ... Journal of Controlled Release 223, 1-10, 2016 | 39 | 2016 |
| Increasing the biological activity of IL-2 and IL-15 through complexing with anti-IL-2 mAbs and IL-15Rα-Fc chimera P Votavova, J Tomala, M Kovar Immunology letters 159 (1-2), 1-10, 2014 | 38 | 2014 |
| Delivery of large heterologous polypeptides across the cytoplasmic membrane of antigen-presenting cells by the Bordetella RTX hemolysin moiety lacking the adenylyl cyclase domain J Holubova, J Kamanova, J Jelinek, J Tomala, J Masin, M Kosova, ... Infection and immunity 80 (3), 1181-1192, 2012 | 37 | 2012 |
| Cyclic AMP-elevating capacity of adenylate cyclase toxin-hemolysin is sufficient for lung infection but not for full virulence of Bordetella pertussis K Skopova, B Tomalova, I Kanchev, P Rossmann, M Svedova, I Adkins, ... Infection and immunity 85 (6), e00937-16, 2017 | 35 | 2017 |
| Caspase-2 and oxidative stress underlie the immunogenic potential of high hydrostatic pressure-induced cancer cell death I Moserova, I Truxova, AD Garg, J Tomala, P Agostinis, PF Cartron, ... Oncoimmunology 6 (1), e1258505, 2017 | 34 | 2017 |
| Chimera of IL-2 linked to light chain of anti-IL-2 mAb mimics IL-2/anti-IL-2 mAb complexes both structurally and functionally J Tomala, J Kovarova, M Kabesova, P Votavova, H Chmelova, ... ACS Chemical Biology 8 (5), 871-876, 2013 | 31 | 2013 |
| The structure of polymer carriers controls the efficacy of the experimental combination treatment of tumors with HPMA copolymer conjugates carrying doxorubicin and docetaxel M Šírová, J Strohalm, P Chytil, O Lidický, J Tomala, B Říhová, T Etrych Journal of Controlled Release 246, 1-11, 2017 | 29 | 2017 |
| Bordetella Adenylate Cyclase Toxin Differentially Modulates Toll-Like Receptor-Stimulated Activation, Migration and T Cell Stimulatory Capacity of Dendritic Cells I Adkins, J Kamanova, A Kocourkova, M Svedova, J Tomala, H Janova, ... PloS one 9 (8), e104064, 2014 | 28 | 2014 |
| IL-2/anti-IL-2 mAb immunocomplexes: A renascence of IL-2 in cancer immunotherapy? J Tomala, M Kovar Oncoimmunology 5 (3), e1102829, 2016 | 27 | 2016 |
| Engineered human cytokine/antibody fusion proteins expand regulatory T cells and confer autoimmune disease protection D VanDyke, M Iglesias, J Tomala, A Young, J Smith, JA Perry, E Gebara, ... Cell reports 41 (3), 111478, 2022 | 25 | 2022 |
| Overcoming Immunoescape Mechanisms of BCL1 Leukemia and Induction of CD8+ T-Cell–Mediated BCL1-Specific Resistance in Mice Cured by Targeted … M Kovar, J Tomala, H Chmelova, L Kovar, T Mrkvan, R Joskova, ... Cancer Research 68 (23), 9875-9883, 2008 | 23 | 2008 |
| Pore‐formation by adenylate cyclase toxoid activates dendritic cells to prime CD8+ and CD4+ T cells M Svedova, J Masin, R Fiser, O Cerny, J Tomala, M Freudenberg, ... Immunology and cell biology 94 (4), 322-333, 2016 | 22 | 2016 |
| Novel IL-2-Poly (HPMA) nanoconjugate based immunotherapy P Votavova, J Tomala, V Subr, J Strohalm, K Ulbrich, B Rihova, M Kovar Journal of Biomedical Nanotechnology 11 (9), 1662-1673, 2015 | 14 | 2015 |
| Synergistic effect of EMF–BEMER-type pulsed weak electromagnetic field and HPMA-bound doxorubicin on mouse EL4 T-cell lymphoma B Říhová, T Etrych, M Šírová, J Tomala, K Ulbrich, M Kovář Journal of Drug Targeting 19 (10), 890-899, 2011 | 13 | 2011 |
| Antitumor activity of IL‐2/anti‐IL‐2 mAb immunocomplexes exerts synergism with that of N‐(2‐hydroxypropyl)methacrylamide copolymer‐bound doxorubicin … J Tomala, H Chmelova, J Strohalm, K Ulbrich, M Sirova, B Rihova, ... International journal of cancer 129 (8), 2002-2012, 2011 | 13 | 2011 |
